Your Javascript appears to be disabled. In order to experience Universe, you need to turn your Javascript on.

TCS Global Virtual Conference - Worldwide Updates & Investments

Online

Toronto, ON, Canada Ontario

43.653226 -79.3831843

Description

The Cannabis Society’s Online Conference Marketplace is connecting growth stage C-Suite with our worldwide network! With the goal to unite the global cannabis community, The Cannabis Society will leverage its online conference platform to facilitate capital injection, joint venture opportunities, and 2020 market developments with executives across international markets. The conference will provide attendees with access to leading cannabis experts through keynotes, panel discussions, and one-on-one breakout meetings through the virtual conference platform. TCS will host the global online conference for the cannabis industry in international markets including Canada, USA, Europe, Australia & New Zealand, South America, and more. On October 27th, the TCS Online Conference Marketplace will focus on Worldwide Updates & Investments. TENTATIVE SCHEDULE (EDT): 11:00 am: Opening Remarks, Welcome and Member Introductions 11:10 am: Keynote by Peter Homberg at Dentons 11:30 am: New Cannabis Developments in Europe David Henn, CEO of Cannamedical Nick Pateras, Managing Director, Europe at Materia Linus Weber, CEO & Founder at Nimbus Health Benedikt Sons, CEO & Co-founder at Cansativa Boris Moshkovits, Co-founder and Managing Director at alephSana Moderated by Peter Homberg, Partner at Dentons 12:15 pm: 1x1 meetings 1:00 pm: IP Protection for Cannabis Products presented by Dr. Martin Huenges from Maiwald 2:00 pm: International Cannabis Investment Panel Bek Muslimov, Co-founding Partner at Leafy Tunnel Alexandre Ouimett-Storrs, Co-founder & Managing Partner at Oskare Capital Kingsley Wilson, Partner at Chrystal Capital Ronnie Jaegermann, Venture Partner at Beyond Ventures Moderated by Thomas Strassner, Partner at Dentons 3:00 pm: North American Cannabis Investment Panel Steve Schuman, Managing Director at HALLEY Venture Partners Tahira Rehmatullah, President at T3 Ventures Matthew Nordgren, CEO & Founder at Arcadian Fund Matt Hawkins, Founder & Managing Partner at Entourage Effect Capital Moderated by Jeffrey Finkle, CEO at Arcview Ventures 4:00 pm: New Cannabis Developments Worldwide Elisabetta Faenza, CEO & Co-founder at LeafCann Group Dr. Sud Agarwal, CEO, Canvalate Brock Lauritsen, CEO at MedGreen Pharmaceutical Howard Katz, Managing Director at Mackie Research Capital Danny Brody, CEO & Co-founder of Elements of Green, CCO at Hempfusion Moderated by Paul Pedersen, CEO, Next Leaf CONFIRMED SPEAKERS: Kingsley Wilson, Partner at Chrystal Capital Kingsley has worked in the regulated financial and investment services industry for over 24 years, spending 10 years as a capital markets research analyst focused on company analysis, portfolio construction and risk mitigation. He has spent the past 14 years advising companies on raising more than $1.5bn of capital across over 100 public and private transactions. Kingsley co-founded Chrystal Capital Partners in 2009 with James Innes. Over the past four years, Kingsley has advised on multiple cannabis investments for various public and private companies, deploying over $210m across 10 cannabis transactions for 375 investors. He has established an extensive network of investor, advisor and company relationships across the cannabis industry and is a regular speaker at industry conferences given his deep industry knowledge and unique European perspective. Kingsley was educated at Cambridge University, before starting his investment banking career in London at Collins Stewart and Investec. Alex Ouimet-Storrs, Co-Founder & Managing Partner as Oskare Capital Alex Ouimet-Storrs is an experienced venture capital investor in Europe with a focus in Deeptech technologies and has a track record of 2.5X and 14.6% IRR, who has invested across the entire life cycle of a company (from Seed to Exit). He began his career at Air Liquide in Paris where he spent 5 years working notably as an Industrial Risk Specialist and Energy Trading for Europe. Following Air Liquide, Alex joined Truffle Capital in 2011 as an Investment Director for the Energy branch of investing which consisted of investing in renewable power generation, energy services companies, materials, internet of things, agriculture and notably next generation chemistry. He was promoted Partner in 2014 and managed a portfolio of 11 companies, has piloted several exits including Actility, Dymeo, ACERDE and Dietswell. Alex joined Solvay Ventures (the corporate venture arm of the Solvay Group) as the Managing Director for the EMEA zone in 2018. He performed two investments in Invizius (Scotland) and Kumovis (Germany) that are developing medical devices. Alex also has experience setting up partnerships between the Solvay group and startups. Alex is the co-founder of Oskare Capital, a 150 MEUR AIFM and ESG compatible fund based in Dublin that will focus on the fast-growing EU medical and pharmaceutical cannabis market. The fund has a strong team comprised of seasoned VCs, medical doctors and researchers, pharma executives and cannabis entrepreneurs. Alex holds a Master’s degree in Chemical Engineering from McGill University (Canada). He co-founded two startups in Canada, one of which won the Quebecois Entrepreneurship Prize in 2005. Matthew Nordgren, CEO & Founder, Arcadian Fund Matthew Jason Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion for creating strategic alliances. He brings breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. Mr. Nordgren is currently CEO and Founder of ARCADIAN Fund and ARCADIAN Capital Management, a venture fund/private equity strategy focused on the ancillary service providing companies in and around the cannabis and hemp industries. More specifically, on Series A/B type opportunities where proven businesses are looking for growth equity to continue scaling into new markets. He was recently name one of the “Top 100 Most Influential People in the Cannabis Industry” by High Times Magazine. Additionally, he is the founder of Nordco Consulting LLC, a private consulting firm dedicated to the business development of middle market companies with forward-thinking vision. To date, Mr. Nordgren has personally been involved with over $7 billion in transactions and maintains a portfolio of approximately 32 companies. Elisabetta Faenza, Co-Founder and CEO, LeafCann Group Member of Australian Institute of Company Directors (MAICD), Deputy Chair Montegu Services Masters International Relations, Dip & Adv. Certificate Clinical Hypnotherapy, Diploma Marketing University of Illinois at Chicago. Elisabetta’s journey was prompted by a childhood diagnosis of a rare, deadly genetic condition, which led her on a quest to understand how our bodies, medicines, nutrition and the environment interact to switch damaging genes on and off. Before co-founding LeafCann Group, a licenced Medicinal Cannabis company based in Australia and the UK, Elisabetta’s work as a clinical hypnotherapist, corporate speaker and mentor assisted thousands of individuals to change unwanted behaviours, recover from trauma and achieve personal and career goals. In LeafCann, Elisabetta has brought together a talented team of experts from biomedicine, clinical research, quality assurance, education and training, controlled medicinal cannabis cultivation, extraction, policy, project management, facility design, regulatory affairs and IP management. Elisabetta manages a global team on three continents, all working to produce the highest quality Medicinal Cannabis products under GMP. Nick Pateras, Managing Director, Europe at Materia Nick Pateras is Managing Director, Europe at Materia, where he oversees the company’s operations across Germany, Denmark, Malta and the UK. Materia is a manufacturer and distributor of medical cannabis and CBD products across the burgeoning European market. Previously, Nick served as Vice President, Strategy at Lift & Co., Canada’s leading cannabis education and insights platform. An early stage employee, he helped scale the company to over sixty people, including a go-public transaction on the TSXV and securing numerous government contracts. He is a regular speaker at cannabis conferences across North America and Europe and taught the Cannabis Business Fundamentals course at George Brown College in Toronto in 2018-19. Prior to his time in cannabis, Nick spent several years in the pharmaceutical sector with Johnson & Johnson Inc, managing various category-leading OTC and Health & Beauty businesses. His background in healthcare led him to make the professional move into cannabis, having long advocated for recognition of its many medical applications. Dr. Sud Agarwal, CEO, Cannvalate Dr. Sud Agarwal is an internationally recognized key opinion leader in the clinical use of medicinal cannabis and is regularly invited as a keynote to key industry and pharmaceutical events including the World Cannabis Conference and the Australian Medicinal Cannabis Conference. Dr. Agarwal is the co-founder and chief executive officer of Cannvalate, Australia’s first medically backed, medicinal cannabis services company, which : Australia’s largest cannabis medicines distributor with a physician network of > 2500 prescribers and 700 pharmacies A University-based, Contract Research Organisation working exclusively in the cannabinoid space delivering drug development solutions to Global Cannabis Companies. He is also the Chief Medical Officer of Incannex Healthcare (ASX:IHL) which is commercializing novel cannabinoid- derived drug assets for: Obstructive Sleep Apnoea Traumatic Brain Injury Sepsis Associated Acute Respiratory Distress Syndrome Dr. Agarwal received his medical qualifications in the United Kingdom before immigrating to Australia in 2001. He has since commercialized, scaled and successfully exited three healthcare businesses and has a track record for seeing business opportunities at their earliest stage, and building high performing, cross-functional teams. Peter Homberg, Partner, Dentons Peter Homberg is a partner in the Dentons Berlin office. He focuses on life sciences, IP, corporate law and M&A transactions in the life sciences and high-tech sector as well as in R&D and cooperation agreements, cross-border IP licensing and IP strategies. Furthermore, he has extensive experience providing legal advice on compliance issues. Additionally, he is the head of the European Cannabis sector group. Peter advises inter alia companies in the pharmaceutical, diagnostics, biotechnology, medical device and medical cannabis industries—from startups to large publicly listed companies. Furthermore, he has broad transactional experience in Southeast Asia. Peter is member of the Licensing Executive Society (LES), the German Association for Intellectual Property and Copyright (GRUR), the German Institution for Arbitration (DIS) as well as the Pharma-Lizenz-Club Deutschland e.V. He regularly holds lectures at seminars and conferences. He is the author of numerous professional articles and other publications regarding corporate or IP law in the field of life sciences. Brock Lauritsen, CEO at MedGreen Pharmaceutical Brock is a business professional and entrepreneur with 10 years of consulting experience evaluating operational efficiencies, scalability and strategies of healthcare companies, as well as 5+ years in the cannabis industry covering all facets of the operation from cultivation through to formulation, marketing, strategy, etc.. As CEO, Brock’s view of the broader landscape and company vision, coupled with the understanding of the day-to-day requirements, provide invaluable tools as MGP scales to meet local and global demand. Tahira Rehmatullah, President at T3 Ventures Tahira Rehmatullah is an investor and advisor to numerous cannabis and hemp businesses and entrepreneurs and has expertise in brand development, investment strategy, and operational growth. She has previously held positions at Hypur Ventures, MTech Acquisition Corp., Marley Natural, Privateer Holdings, City First Enterprises, Perry Capital, and Ernst & Young, and currently serves as President of T3 Ventures, Partner at Highlands Venture Partners, and on the board of directors of Akerna Corp., Ceres Acquisition Corp., and Superette. An established thought leader in the space, Tahira is a frequent speaker at conferences and events around the world and has been featured in press outlets such as Forbes, Business Insider, Fortune, Marie Claire, Yahoo Finance, and Rolling Stone. She also serves on the advisory board of The Initiative and the Last Prisoner Project, and is dedicated to developing female and minority leadership in the industry. Tahira earned her MBA from the Yale School of Management and B.S. in Finance and minor in Life Sciences from The Ohio State University. She resides in New York City. Howard Katz, Managing Director at Mackie Research Capital Howard is a 20 year capital markets veteran with a broad range of experience including both financing and advisory mandates to a wide range of sectors in the Canadian markets. Howard also has extensive management experience as a successful CEO having profitably sold his privately-held company in 2016. As a senior investment banker, Howard has led or co-managed billions of dollars in the junior and mid-cap sector in Canada. Howard is focused on the technology sector and special situations, providing advisory and finance solutions to clients, whereby leading management teams can share their successes with investors. Howard is a graduate of Yeshiva University, and earned his MBA from the Schulich School of Business. Benedikt Sons, CEO & Co-Founder of Cansativa Benedikt Sons is CEO and Co-Founder of Cansativa. He holds a Bachelor’s and Master’s degree in industrial engineering and management. Prior to co-founding Cansativa, Benedikt worked in the field of strategy consulting within pharma and automotive industry. He has a wealth of knowledge about every aspect of how to run a cannabis business in Europe, from regulations to logistics and markets. Benedikt is responsible for strategy as well as all business and commercial matters at Cansativa. Linus Maximillian Weber, Founder & CEO of Nimbus Health Linus Maximilian Weber is an experienced Business Consultant, Founder and Chief Executive in the health care industry. Linus has been working at Ernst & Young in the Compliance and Quality Management Consulting unit prior joining Fresenius Medical Care the worlds leading company in renal care. He is a certified Project Management Consultant and GDP Responsible for the pharmaceutical distribution business. In 2018 after building the Compliance Management System at Fresenius he founded Nimbus Health a fully licensed pharmaceutical wholesaler and manufacturer in Germany, where he serves as Chief Executive Officer. The focus of Nimbus Health is to improve the wellbeing of patients by giving consistent and standardized access to alternative therapies based on Medicinal Cannabis and to reshape the health care system by developing additional Cannabis products. Danny Brody, CEO & Co-founder of Elements of Green, CCO at HempFusion Mr. Brody started his career in the brokerage industry, working at two leading independent brokerage firms. He learned the intricacy of financing business and what it takes to build successful companies from management, to share structures, to the IPO process, and beyond. After this foundation was firmly established, in 2013, he made the switch to the company side and began working in Cannabis with private and public companies.Fast forward to 2020, he and his team have founded and partnered with numerous cannabis companies and completed multiple successful IPO's including Emblem Cannabis (Acquired, 2018), The Green Organic Dutchman, where he and his partners completed the largest cannabis IPO ever, at its time, raising $132.1 million in 2018, followed by PLUS Products. The team has now entered the US and European CBD market with a partnership with HempFusion, and the founding of Europe's Premier e-commerce CBD marketplace: Elements of Green.Mr. Brody is currently the CEO of Elements of Green and TGOD Acquisitions Corp., Partner at RADD Capital, and Chief Corporate Officer at HempFusion. Bek Muslimov, Co-founding Partner at Leafy Tunnel Bek is a co-founding Partner at Leafy Tunnel, London-based investment firm dedicated to investing in early-stage medical cannabis companies in Europe as well as in companies focused on bringing plant-based therapies into mental health and palliative care markets across the globe. For the past 7 years he has been investing in European technology and life science companies. His recent investments at Leafy Tunnel includes Wundr Co., ATAI Life Sciences and Synthesis Institute. Prior to Leafy Tunnel Bek has been an Investment Director at Blue Wire where he has led investments in Monzo, Superawesome, Homehero, Ocean Harvest, Ihateironing. MBA graduate of London Business School, Bek has completed a medical neuroscience course at Duke University and medical cannabis specialisation at University of Colorado Boulder. David Henn, Founder & CEO of Cannamedical Pharma David is the founder and CEO of Cannamedical Pharma. As a first mover in the industry he is a key driver of the Company's growth, on-going vision and structuring. David's primary focus has been to generate strategic partnerships around the globe and identifying growth opportunities. He is responsible for overseeing all management for the organization, advancing corporate market strategy, regulatory affairs, fostering an entrepreneurial spirit throughout the Company. Cannamedical is continually expanding and has already established European subsidiaries that are in the progress of obtaining additional production and distribution licenses for the company. Steve Schuman, Managing Director at HALLEY Venture Partners Mr. Schuman is the Managing Director of HALLEY Venture Partners, L.P., a venture investment firm he founded in 2017 that focuses on building the best technology companies in the legal cannabis and hemp industries. Mr. Schuman has 18 years of public and private equity investment experience in agriculture, technology, and manufacturing. From 2010-2016, Mr. Schuman was a Senior Analyst and Portfolio Manager for Passport Capital, LLC, a multi-billion dollar investment management firm headquartered in San Francisco. Prior to Passport, Mr. Schuman was a Senior Sell-Side Equity Analyst at Prudential Equity Group covering the agriculture and chemical industries. Mr. Schuman started his career in engineering at Cargill and Dow AgroSciences. He has worked for Fortune 100 corporations as well as multiple start-up companies. Mr. Schuman received a B.S. in Chemical Engineering from The Ohio State University and an MBA from The Haas School of Business at the University of California at Berkeley, where he was a Mayfield Venture Capital Fellow. Ronnie Jaegermann, Venture Partner at Beyond Ventures Highly experienced Entrepreneur and Investment Banker. Dealmaker. Crowdfunding expert. Long-lasting experience in growing a business from being a start-up to a selling profitable company. Involved in successful fundraising for Israeli technology companies in the last 25 years of over $350M on different international stock exchanges. Vast experience in international business. Special expertise in raising capital from private investors. Special understanding of the retail and high-tech industries. Concentrating on raising capital through RTO's on the TSXV the Toronto Stock Exchange venture and raising capital on the Canadian Securities Exchange ( The CSE). Raising capital for Cannabis ventures. Director in publicly traded companies in Canada. Thomas Strassner, Partner at Dentons Thomas Strassner is a partner in Dentons´ Munich office and member of the Europe Board. He has extensive experience in corporate law matters, venture capital, private equity and M&A transactions, joint ventures and corporate restructurings. Tom has advised on numerous international and cross-border transactions and restructurings of companies and corporations. Among his clients are international investors, family offices as well as (privately held and listed) companies from high-growth startups to industry leaders from different sectors, including asset-focused & producing businesses, information technology, health care and life sciences. Prior to joining Dentons, Tom was at another US-based law firm and served as legal counsel for a venture capitalist. Tom attended Copenhagen Business School and the University of Munich, where he received his degrees in business (Dipl.-Kfm.) and law. A member of the Munich Bar Association, Tom is admitted to practice law in Germany. Jeffrey Finkle, CEO at Arcview Ventures Named one of the “25 Angel Investors in New York You Need to Know” by AlleyWatch in 2014, Jeff has been a venture investor for ten years, an angel investor for eight years. Jeff is presently Co-founder of the Viridian Members Fund, the first member-managed fund in cannabis. He also serves as Chairman of the Evaluation Committee and Treasurer of the ARC Angel Fund. Jeff has been actively advising startups at Reitler Advisory Group and publishes insights to his blog www.finkabout.it. He is a frequent panelist, speaker, and judge on venture investing and pitch competitions in NY. Jeff has also guest lectured and held office hours for many incubators/accelerators including Start-up Leadership Program, 37 Angels, NYU Polytech Incubator (New York City and Brooklyn), DreamIT Ventures, and FashInvest. Prior to his work with angel and seed groups, Jeff was a partner of Odeon Capital Partners, an early-stage venture capital fund. Prior to Odeon, Jeff was an operating executive at CA, Inc., and Cheyenne Software, Inc., where he served as GM of the Unix Division, VP of Corporate Development, VP of Corporate Marketing, and Director of Product Management. Jeff also serves as Chairman of the Board of WellLife Network , a not-for-profit offering residential, clinical, and day programs to 25,000 individuals with developmental, psychological, and behavioral disabilities in NYC’s five boroughs and Long Island. Paul Pederson, CEO & Co-founder at NextLeaf Solutions Paul Pedersen is co-founder and CEO of Nextleaf Solutions (CSE: OILS), a Vancouver-based company developing technology for extracting and distilling THC and CBD oils. Paul has been focused on the cannabis industry since 2013, working with entrepreneurs and startups including Canada’s first legal cannabis oil producer, acquired in 2016 by The Cronos Group (TSE: CRON). Previously, Paul founded a media company that was acquired in 2007 by Towerstream Corporation (NASDAQ: TWER), and spent 10 years in capital markets. Paul holds a MBA in Finance from the Eli Broad Graduate School of Management at Michigan State University – where he served as a Fellow at the Center for Venture Capital Private Equity and Entrepreneurial Finance – and a Bachelors of Commerce Degree from the Sobey School of Business at Saint Mary’s University. Paul grew up in Langley, B.C. in a dairy farming family. Boris Moshkovits, Co-founder and Managing Director, alephSana Boris Moshkovits is a Cannapreneur and experienced founder with a demonstrated history of working in the media, pharma and internet industry. He is the co-founder and managing director of alephSana, a company focused on scouting for qualified medicinal cannabis products globally and on bringing the best cannabis therapeutics to Germany and Europe. Moshkovits has served as International digital marketing manager in the pharma industry walking the fine line of marketing and digital storytelling in highly regulated markets. As a speaker Moshkovits has been talking about the mainstreaming of medicinal cannabis and the future of cannabis as a medicine. He I son the industry board of the Medicinal Cannabis Congress for doctors and also the co-founder of the CannaBusinessClub.Berlin, an initiative to empower the local cannabis scene. Dr. Martin Huenges, Partner at Maiwald Martin Huenges advises and represents clients from Europe, the USA and Japan in the fields of biotechnology and pharmaceuticals in securing, defending and enforcing intellectual property rights in Germany, Europe and worldwide. He prepares freedom-to-operate and validity opinions and represents clients in opposition and nullity proceedings. In advising clients on patent strategy, he can draw on many years of legal and scientific experience, in particular in the fields of medical indications, biomarkers, diagnostic assays and vaccines. He has particular expertise in conducting and coordinating complex opposition and appeal proceedings before the European Patent Office. Matt Hawkins, Founder & Managing Partner at Entourage Effect Capital Matt Hawkins is the founder and managing principal of Entourage Effect Capital (EEC), formerly known as Cresco Capital Partners, a venture capital firm focused specifically on investing in the legalized cannabis industry. Since 2014, the firm has made close to 70 investments invested out of two funds, co-investment vehicles and special purpose entities. Prior to the founding of EEC, he was a partner and President of a private real estate investment company which acquired REO and NPL from banks and financial institutions across the country, with particular interest in multifamily residential and self-storage assets. The company completed more than 55 bank-direct acquisitions, deploying over $500MM of capital since Q4 2008. In 2013 alone, the company bought close to 10,000 Class B and Class C value-add multifamily units across the Sunbelt of the United States. At the end of 2013, Matt and his partners sold their interest. Prior to this, Matt was a Principal/ Co-founder of San Jacinto Partners, a fund focused on the bulk acquisition of single family residential assets and the Managing General Partner of Adjacent Capital, L.P., a private equity/specialty lending fund. He was earlier affiliated with Treadstone Partners, L.L.C., a distressed debt and equity fund. He has an extensive background in both turnaround management and private equity. Prior to joining Treadstone and forming Adjacent Capital and San Jacinto Partners, was associated with Hull & Associates, a regional turnaround management firm. Matt is a graduate of The University of Texas at Austin. Founder and Managing Principal of Cresco Capital Partners, LLC, a private equity firm focused on investing in the legalized cannabis industry. Since 2014, the firm has invested out of two funds, has close to $100MM in AUM, and is currently raising its third fund. Prior to CCP, Hawkins was a partner of a private investment company which acquired REO and NPL from banks and financial institutions across the country. The company completed more than 55 bank-direct acquisitions, deploying over $500MM of capital. At the end of 2013, Hawkins and his partners sold their interest. Hawkins is a graduate of The University of Texas at Austin.

This listing has no upcoming events

Start: 2020-10-27T11:00:00-04:00

End: 2020-10-27T17:00:00-04:00

Tickets

General Admission 99.0 USD

1x1 Meetings Ticket Package 999.0 USD